|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/7034 | |
| A61K 31/551 | |||
| A61K 31/4515 | |||
| A61P 3/04 | |||
| A61P 3/06 | |||
| A61P 3/08 |
| (11) | Patento numeris | 2714052 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12724631.2 |
| Europos patento paraiškos padavimo data | 2012-05-31 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-04-09 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-09-19 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2012/060194 |
| Data | 2012-05-31 |
| (87) | Numeris | WO 2012/163990 |
| Data | 2012-12-06 |
| (30) | Numeris | Data | Šalis |
| 11168641 | 2011-06-03 | EP | |
| 12153052 | 2012-01-30 | EP |
| (72) |
WIENRICH, Marion, DE
MAYOUX, Eric, DE
|
| (73) |
Boehringer Ingelheim International GmbH,
Binger Strasse 173, 55216 Ingelheim am Rhein,
DE
|
| (54) | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS |
| SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS |